Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial
In the context of a clinical trial, participants should contact their trial site medical team as the first point of contact for any concerning symptoms
Brand-name Wegovy is now accessible at $349 per month for cash-paying patients, a 74% reduction from the $1,349 list price that previously made the medication unaffordable for most people without insurance coverage
REGEN shows strongest effects for soft tissue injuries including tendinitis, ligament sprains, muscle strains, and partial tears
Gastrointestinal events dominate the reported tolerability profile of all three
The maximum approved dose may be different if retatrutide is licensed in the future